Rufy3 Knockdown Induces <scp>PANoptosis</scp> Through <scp>MAP4</scp> / <scp>CDK1</scp> Axis to Inhibit Colorectal Cancer Growth: Evidence From In Vitro and In Vivo Models

Colorectal cancer (CRC) has a high morbidity and mortality. PANoptosis is a phenomenon in which metabolism and cell death are closely related. However, the underlying molecular mechanism of PANoptosis in CRC is still unclear. Co-IP was used to detect the binding between Rufy3 and MAP4, and MAP4 and CDK1. Western blot and immunofluorescence assays were used to detect the expression of Rufy3 in different cell lines. Mouse xenograft models demonstrated the anti-tumor effects of Rufy3 knockdown. Co-IP showed there exists a binding between Rufy3 and MAP4, MAP4 and CDK1. Among the cell lines, the expression level of Rufy3 in LoVo cells was the highest. Knocking down Rufy3 slowed down the growth of the tumor and increased the PANoptosis of the tumor. These results collectively provide mechanistic insight into the impact of Rufy3 on CRC through PANoptosis and can be a useful therapeutic approach in patients with CRC.